Partnering with Tempus provides access to an integrated multi-omic analytical platform and artificial intelligence capabilities designed to accelerate scientific discoveries.
Institutions can access 3.8 million de-identified patient records, proprietary technologies to explore and identify patterns in the data, and a path for collaborative research with Tempus.
Leverage the Tempus database to explore, power, and validate a hypothesis in precision oncology, aiming to produce presentations and publications.
Tempus has additional capabilities including single-cell sequencing, genome-wide liquid biopsy profiling, spatial transcriptomics, methylation, genotyping and more.
Learn more about our sequencing capabilitiesWe provide key clinical findings for microsatellite instability (MSI) status, tumor mutational burden (TMB), and when applicable, PD-L1 IHC results. We also report insights for research related to therapeutic resistance risk and RNA expression of immunotherapy targets (e.g., PD-L1, CTLA-4), and biologically-relevant findings such as neoantigen prediction, HLA genotyping, and tumor immune infiltration.
At the Tempus|M modeling lab, a state of the art in-vitro facility, we use ex vivo tumor organoid biological modeling to understand the consequence of cancer genome alterations on growth, therapeutic sensitivity, and immune evasion.
Read the abstractWe leverage the genomic- and clinically-annotated organoid library through a suite of experimental capabilities on our customized platforms spanning high-throughput screening, high-content imaging, next-generation and single-cell sequencing, effector cell co-culture experiments, and standard histopathology capabilities. We work in close collaboration with our partners to offer a bespoke set of services in order to maximize value that may lead to further inquiry with other Tempus resources such as real-world and molecular data.
Organoid Development
Using the Tempus xT assay on ex vivo tumors, Tempus correlates clinical patients’ responses with expanded real world cohorts, then further broadens these data sets with tumor organoids possessing somatic mutations or RNA expression signatures of interest to develop a model of universal concordance. Tempus organoid panels have the potential to validate hypotheses and observations from real world data; discover novel pathways and tumor drivers; and construct large scale data sets of in vitro sensitivities across hundreds of unique patients ex vivo for any given cancer, or target of interest.
Molecular Profiling
Tumor organoids are characterized by the Tempus xT 648 gene-panel and whole transcriptome analysis including copy number prediction. An informatics pipeline is used to compare mutational recapitulation between the organoid models and the originating patient’s tumor. Organoids are also annotated for genome-wide analyses such as MSI and Homologous Recombination Deficiency (HRD).
Therapeutic Profiling
Tumor organoids can be used to study established small molecules, antibody drug conjugates and effector cell systems such as CAR-T or CAR-NK. Tumor organoid response is evaluated with a robust and reproducible high content and machine learning based assay.
Our highly-automated research image analysis is optimized around advanced pattern recognition and data characterization. The program is designed to quantify various tumor characteristics in a non-invasive and objective way. Our complex machine-learning algorithms are constantly running in the background, which allows us to improve the speed and accuracy of our insights engine in near real time.
Our web-based pathology and radiology platforms, combined with state-of-the-art image analysis tools, are designed to enable pathologists and researchers to access, share, and analyze images anywhere at any time for research purposes.
Request a Demo
At Tempus, our research partnership approach focuses on end to end solutions with the ability to customize deliverables and adapt projects to different sizes and budgets. We combine concierge service from our research operations team, scientific and medical expertise, multiple state of the art labs, and our continuously growing multimodal database, to deliver on research projects quickly and efficiently. We leverage our data & technology background to make your research usable and useful, with the goal of getting you from data to insights in minutes, not months.
Tempus generates, organizes, and analyzes extensive amounts of data to support providers in identifying relevant and actionable clinical trials for their patients. Our TIME Trial® Program enables providers in the network to have access to a portfolio of clinical trials and expand treatment options for their patients. All participants in the TIME Trial® Program utilize a pre-packaged clinical trial agreement, a pre-negotiated budget, a central IRB, and a team of dedicated Tempus research liaisons to help shorten trial start from months into weeks.
Learn more